Overview
Terns reports Q3 net loss of $24.6 mln, less than analysts' expectations
Company highlights promising Phase 1 CARDINAL trial results for TERN-701 in CML
Terns shifts focus to oncology, seeks partners for metabolic programs
Outlook
Company expects cash reserves to support operations into 2028
Terns to present expanded CARDINAL trial data at ASH meeting in December 2025
Company seeks strategic partners for TERN-501 and TERN-801 programs
Result Drivers
STRATEGIC FOCUS - Terns shifts focus to oncology, seeks partners for metabolic programs
EXPENSES: R&D expenses rose to $19.9 mln from $15.2 mln last year, while G&A expenses fell to $7.8 mln from $9.8 mln.
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | Beat | -$24.64 mln | -$27.35 mln (8 Analysts) |
Q3 Income from Operations | Beat | -$27.72 mln | -$29.88 mln (9 Analysts) |
Q3 Pretax Profit | Beat | -$24.59 mln | -$27.34 mln (8 Analysts) |
Q3 Basic EPS | -$0.27 | ||
Q3 Operating Expenses | $27.72 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Terns Pharmaceuticals Inc is $25.00, about 26.1% above its November 7 closing price of $18.47
Press Release: ID:nGNX8fGp8q
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)